Author
Listed:
- Paulo Rodrigues
(Group of Molecular Oncology, CIBBIM-Nanomedicine, Vall d’Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona
CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN))
- Irati Macaya
(Group of Molecular Oncology, CIBBIM-Nanomedicine, Vall d’Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona
CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN))
- Sarah Bazzocco
(Group of Molecular Oncology, CIBBIM-Nanomedicine, Vall d’Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona
CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN))
- Rocco Mazzolini
(Group of Molecular Oncology, CIBBIM-Nanomedicine, Vall d’Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona
CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN))
- Elena Andretta
(Group of Molecular Oncology, CIBBIM-Nanomedicine, Vall d’Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona
CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN))
- Higinio Dopeso
(Group of Molecular Oncology, CIBBIM-Nanomedicine, Vall d’Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona
CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN))
- Silvia Mateo-Lozano
(Group of Molecular Oncology, CIBBIM-Nanomedicine, Vall d’Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona
CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN))
- Josipa Bilić
(Group of Molecular Oncology, CIBBIM-Nanomedicine, Vall d’Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona
CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN))
- Fernando Cartón-García
(Group of Molecular Oncology, CIBBIM-Nanomedicine, Vall d’Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona
CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN))
- Rocio Nieto
(Group of Molecular Oncology, CIBBIM-Nanomedicine, Vall d’Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona
CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN))
- Lucia Suárez-López
(CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN)
Group of Drug Delivery and Targeting, CIBBIM-Nanomedicine, Vall d’Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona)
- Elsa Afonso
(Group of Molecular Oncology, CIBBIM-Nanomedicine, Vall d’Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona
CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN))
- Stefania Landolfi
(Vall d’Hebron Hospital)
- Javier Hernandez-Losa
(Vall d’Hebron Hospital)
- Kazuto Kobayashi
(Institute of Biomedical Sciences, Fukushima Medical University School of Medicine)
- Santiago Ramón y Cajal
(Vall d’Hebron Hospital)
- Josep Tabernero
(Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona)
- Niall C. Tebbutt
(Ludwig Institute for Cancer Research, Melbourne-Branch, Austin Health)
- John M. Mariadason
(Ludwig Institute for Cancer Research, Melbourne-Branch, Austin Health)
- Simo Schwartz
(CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN)
Group of Drug Delivery and Targeting, CIBBIM-Nanomedicine, Vall d’Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona)
- Diego Arango
(Group of Molecular Oncology, CIBBIM-Nanomedicine, Vall d’Hebron University Hospital, Research Institute (VHIR), Universitat Autònoma de Barcelona
CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN))
Abstract
Activation of the small GTPase RHOA has strong oncogenic effects in many tumour types, although its role in colorectal cancer remains unclear. Here we show that RHOA inactivation contributes to colorectal cancer progression/metastasis, largely through the activation of Wnt/β-catenin signalling. RhoA inactivation in the murine intestine accelerates the tumorigenic process and in human colon cancer cells leads to the redistribution of β-catenin from the membrane to the nucleus and enhanced Wnt/β-catenin signalling, resulting in increased proliferation, invasion and de-differentiation. In mice, RHOA inactivation contributes to colon cancer metastasis and reduced RHOA levels were observed at metastatic sites compared with primary human colon tumours. Therefore, we have identified a new mechanism of activation of Wnt/β-catenin signalling and characterized the role of RHOA as a novel tumour suppressor in colorectal cancer. These results constitute a shift from the current paradigm and demonstrate that RHO GTPases can suppress tumour progression and metastasis.
Suggested Citation
Paulo Rodrigues & Irati Macaya & Sarah Bazzocco & Rocco Mazzolini & Elena Andretta & Higinio Dopeso & Silvia Mateo-Lozano & Josipa Bilić & Fernando Cartón-García & Rocio Nieto & Lucia Suárez-López & E, 2014.
"RHOA inactivation enhances Wnt signalling and promotes colorectal cancer,"
Nature Communications, Nature, vol. 5(1), pages 1-15, December.
Handle:
RePEc:nat:natcom:v:5:y:2014:i:1:d:10.1038_ncomms6458
DOI: 10.1038/ncomms6458
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:5:y:2014:i:1:d:10.1038_ncomms6458. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.